Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr/Abl

Molecular Nutrition and Food Research

Volumn 56, Issue 9, 2012, Pages 1398-1412

  Chen, Ying Jung ^a   Chang, Long Sen ^a,b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AP 1; Bcr Abl; Gallic acid; JNK1; MMP 2 MMP 9

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; GALLIC ACID; GELATINASE A; GELATINASE B; MMP2 PROTEIN, HUMAN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL STRAIN K 562; DOWN REGULATION; DRUG EFFECT; GENETICS; HUMAN; LEUKEMIA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 2; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; GALLIC ACID; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; LEUKEMIA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84865706224     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200167     Document Type: Article

References (72)

1. Niemetz, R., Gross, G. G., Enzymology of gallotannin and ellagitannin biosynthesis. Phytochemistry 2005, 66, 2001-2011.
2. Kang, M. S., Oh, J. S., Kang, I. C., Hong, S. J. et al., Inhibitory effect of methyl gallate and gallic acid on oral bacteria. J. Microbiol. 2008, 46, 744-750.
3. Kim, S. H., Jun, C. D., Suk, K., Choi, B. J. et al., Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol. Sci. 2006, 91, 123-131.
4. Inoue, M., Suzuki, R., Sakaguchi, N., Li, Z. et al., Selective induction of cell death in cancer cells by gallic acid. Biol. Pharm. Bull. 1995, 18, 1526-1530.
5. 1 phase arrest and apoptosis in human leukemia HL-60 cells through inhibiting cyclin D and E, and activating mitochondria-dependent pathway. Anticancer Res. 2011, 31, 2821-2832.
6. Agarwal, C., Tyagi, A., Agarwal, R., Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol. Cancer Ther. 2006, 5, 3294-3302.
7. Kaur, M., Velmurugan, B., Rajamanickam, S., Agarwal, R. et al., Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, proapoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice. Pharm. Res. 2009, 26, 2133-2140.
8. Veluri, R., Singh, R. P., Liu, Z., Thompson, J. A. et al., Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. Carcinogenesis 2006, 27, 1445-1453.
9. Kawada, M., Ohno, Y., Ri, Y., Ikoma, T. et al., Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice. Anticancer Drugs 2001, 12, 847-852.
10. Ohno, Y., Fukuda, K., Takemura, G., Toyota, M. et al., Induction of apoptosis by gallic acid in lung cancer cells. Anticancer Drugs 1999, 10, 845-851.
11. You, B. R., Park, W. H., Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase. Toxicol. In Vitro 2010, 24, 1356-1362.
12. Maurya, D. K., Nandakumar, N., Devasagayam, T. P., Anticancer property of gallic acid in A549, a human lung adenocarcinoma cell line, and possible mechanisms. J. Clin. Biochem. Nutr. 2011, 48, 85-90.
13. Lo, C., Lai, T. Y., Yang, J. H., Yang, J. S. et al., Gallic acid induces apoptosis in A375.S2 human melanoma cells through caspase-dependent and -independent pathways. Int. J. Oncol. 2010, 37, 377-385.
14. Lo, C., Lai, T. Y., Yang, J. S., Yang, J. H. et al., Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras. Melanoma Res. 2011, 21, 267-273.
15. Faried, A., Kurnia, D., Faried, L. S., Usman, N. et al., Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int. J. Oncol. 2007, 30, 605-613.
16. You, B. R., Moon, H. J., Han, Y. H., Park, W. H., Gallic acid inhibits the growth of HeLa cervical cancer cells via apoptosis and/or necrosis. Food Chem. Toxicol. 2010, 48, 1334-1340.
17. Chen, H. M., Wu, Y. C., Chia, Y. C., Chang, F. R. et al., Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate cancer cells. Cancer Lett. 2009, 286, 161-171.
18. Liu, K. C., Ho, H. C., Huang, A. C., Ji, B. C. et al., Gallic acid provokes DNA damage and suppresses DNA repair gene expression in human prostate cancer PC-3 cells. Environ. Toxicol. 2011. doi:10.1002/tox.20752.
19. Raina, K., Rajamanickam, S., Deep, G., Singh, M. et al., Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. Mol. Cancer Ther. 2008, 7, 1258-1267.
20. Mediero, G., Alonso, F., Borda, P., Galan, L. et al., Effect of polyphenols from the Mediterranean diet on proliferation and mediators of in vitro invasiveness of the MB-49 murine bladder cancer cell line. Actas Urol. Esp. 2005, 29, 743-749.
21. Ho, H. H., Chang, C. S., Ho, W. C., Liao, S. Y. et al., Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-κB activity and downregulation of PI3K/AKT/small GTPase signals. Food Chem. Toxicol. 2010, 48, 2508-2516.
22. Lu, Y., Jiang, F., Jiang, H., Wu, K. et al., Gallic acid suppresses cell viability, proliferation, invasion and angiogenesis in human glioma cells. Eur. J. Pharmacol. 2010, 641, 102-107.
23. Liu, K. C., Huang, A. C., Wu, P. P., Lin, H. Y. et al., Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncol. Rep. 2011, 26, 177-184.
24. Liao, C. L., Lai, K. C., Huang, A. C., Yang, J. S. et al., Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem. Toxicol. 2012, 50, 1734-1740.
25. Klein, G., Vellenga, E., Fraaije, M. W., Kamps, W. A. et al., The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 2004, 50, 87-100.
26. Egeblad, M., Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
27. 2+/ROS-mediated suppression of ERK/c-Fos pathway and activation of p38 MAPK/c-Jun pathway. J. Cell. Physiol. 2010, 224, 775-785.
28. Liu, W. H., Chang, L. S., Adaphostin promotes caffeine-evoked autoacrine Fas-mediated death pathway activation in Bcr/Abl-positive leukemia cells. Biochem. J. 2011, 439, 453-467.
29. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S. et al., The biology of chronic myeloid leukemia. N. Eng. J. Med. 1999, 341, 167-172.
30. Hochhaus, A., Kreil, S., Corbin, A. S., La Rosee, P. et al., Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16, 2190-2196
31. Donata, N. J., Wu, J. Y., Stapley, J., Lin, H. et al., Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64, 672-677
32. Chandra, J., Hackbarth, J., Loegering, S. L. D., Bone, N. et al., Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003, 102, 4512-4519
33. Kantarjian, H. M., Giles, F., Quintas-Cardama, A., Cortes, J., Important therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res. 2007, 13, 1089-1097
34. Chen, Y. J., Wang, J. J., Chang, L. S., Naja nigricollis CMS-9 enhances mitochondria-mediated death pathway in adaphostin-treated human leukemia U937 cells. Clin. Exp. Pharmacol. Physiol. 2011, 38, 755-763.
35. Puccetti, E., Guller, S., Orleth, A., Bruggenolte, N. et al., BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res. 2000, 60, 3409-3413.
36. Hakansson, P., Lassen, C., Olofsson, T., Baldetorp, B. et al., Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). Leukemia 2004, 18, 538-547.
37. Tian, W., Luo, H., Yuan, Y., Huang, S. et al., Antiproliferation effect of β-TrCP ubiquitin ligase mediated Bcr-Abl protein degradation in leukemia K562 cells. Chin. J. Clin. Oncol. 2010, 37, 66-70.
38. Wei, S., Chuang, H. C., Tsai, W. C., Yang, H. C. et al., Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of β-transducin repeat-containing protein. Mol. Pharmacol. 2009, 76, 47-57.
39. Donata, N. J., Wu, J. Y., Stapley, J., Lin, H. et al., Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64, 672-677
40. von Gise, A., Lorenz, P., Wellbrock, C., Hemmings, B. et al., Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol. Cell Biol. 2001, 21, 2324-2336.
41. Sato, S., Fujita, N., Tsuruo, T., Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J. Biol. Chem. 2004, 279, 33759-33767.
42. Benbow, U., Brinckerhoff, C. E., The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol. 1997, 15, 519-526.
43. Crowe, D. L., Brown, T. N., Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion. Neoplasia 1999, 1, 368-372.
44. Song, H., Ki, S. H., Kim, S. G., Moon, A., Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res. 2006, 66, 10487-10496.
45. Kim, E. S., Sohn, Y. W., Moon, A., TGF-β-induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF)2 in human breast epithelial cells. Cancer Lett. 2007, 252, 147-156.
46. Hasegawa, H., Senga, T., Ito, S., Iwamoto, T. et al., A role for AP-1 in matrix metalloproteinase production and invadopodia formation of v-Crk-transformed cells. Exp. Cell Res. 2009, 315, 1384-1392.
47. Singh, N. K., Quyen, D. V., Kundumani-Sridharan, V., Brooks, P. C. et al., AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15S-hydroxyeicosatetraenoic acid-induced angiogenesis. J. Biol. Chem. 2010, 285, 16830-16843.
48. Lopez-Bergami, P., Lau, E., Ronai, Z., Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer. 2010, 10, 65-76.
49. Konishi, Y., Hitomi, Y., Yoshioka, E., Intestinal absorption of p-coumaric and gallic acids in rats after oral administration. J. Agric. Food Chem. 2004, 52, 2527-2532.
50. Konishi, Y., Kobayashi, S., Shimizu, M., Transepithelial transport of p-coumaric acid and gallic acid in Caco-2 cell monolayers. Biosci. Biotechnol. Biochem. 2003, 67, 2317-2324.
51. Manach, C., Williamson, G., Morand, C., Scalbert, A. et al., Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S-242S.
52. Shahrzad, S., Aoyagi, K., Winter, A., Koyama, A. et al., Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. J. Nutr. 2001, 131, 1207-1210.
53. Roberts, A. T., Martin, C. K., Liu, Z., Amen, R. J. et al., The safety and efficacy of a dietary herbal supplement and gallic acid for weight loss. J. Med. Food 2007, 10, 184-188.
54. Ferruzzi, M. G., Lobo, J. K., Janle, E. M., Cooper, B. et al., Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J. Alzheimers Dis. 2009, 18, 113-124.
55. Demeule, M., Michaud-Levesque, J., Annabi, B., Gingras, D. et al., Green tea catechins as novel antitumor and antiangiogenic compounds. Curr. Med. Chem. Anticancer Agents 2002, 2, 441-463.
56. Kandaswami, C., Lee, L. T., Lee, P. P., Hwang, J. J. et al., The antitumor activities of flavonoids. In Vivo 2005, 19, 895-909
57. Demeule, M., Brossard, M., Page, M., Gingras, D. et al., Matrix metalloproteinase inhibition by green tea catechins. Biochim. Biophys. Acta 2000, 1478, 51-60.
58. Kim, H. S., Kim, M. H., Jeong, M., Hwang, Y. S. et al., EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res. 2004, 24, 747-753.
59. Vijayababu, M. R., Arunkumar, A., Kanagaraj, P., Venkataraman, P. et al., Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol. Cell Biochem. 2006, 287, 109-116.
60. Sen, T., Dutta, A., Chatterjee, A., Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs 2010, 21, 632-644.
61. Sen, T., Moulik, S., Dutta, A., Choudhury, P. R. et al., Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci. 2009, 84, 194-204.
62. Saragusti, A. C., Ortega, M. G., Cabrera, J. L., Estrin, D. A. et al., Inhibitory effect of quercetin on matrix metalloproteinase 9 activity molecular mechanism and structure-activity relationship of the flavonoid-enzyme interaction. Eur. J. Pharmacol. 2010, 644, 138-145.
63. Yan, C., Boyd, D. D., Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 2007, 211, 19-26.
64. Crowe, D. L., Tsang, K. J., Shemirani, B., Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia 2001, 3, 27-32.
65. Simon, C., Simon, M., Vucelic, G., Hicksc, M. J. et al., The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp. Cell Res. 2001, 271, 344-355.
66. Janowska-Wieczorek, A., Majka, M., Marquez-Curtis, L., Wertheim, J. A. et al., Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002, 16, 1160-1166.
67. Narla, R. K., Dong, Y., Klis, D., Uckun, F. M., Bis(4, 7-dimethyl-1, 10-phenanthroline) sulfatooxovanadium(I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. Clin. Cancer Res. 2001, 7, 1094-1101.
68. Kaneta, Y., Kagami, Y., Tsunoda, T., Ohno, R. et al., Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int. J. Oncol. 2003, 23, 681-691.
69. Kim, J. G., Sohn, S. K., Kim, D. H., Baek, J. H. et al., Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk. Lymphoma 2005, 46, 885-891.
70. Krasowska-Kwiecien, A., Kijowski, J., Lukasiewicz, E., Sacha, T. et al., Angiogenesis in different clinical phases of chronic myeloid leukemia. Przegl. Lek. 2009, 66, 471-478.
71. Serrano, J., Cipak, A., Boada, J., Gonzalo, H. et al., Double-edged sword behaviour of gallic acid and its interaction with peroxidases in human microvascular endothelial cell culture (HMEC-1). Antioxidant and pro-oxidant effects. Acta Biochim. Pol. 2010, 57, 193-198.
72. Locatelli, C., Carvalho, D. R., Mascarello, A., de Cordova, C. A. et al., Antimetastatic activity and low systemic toxicity of tetradecyl gallate in a preclinical melanoma mouse model. Invest. New Drugs 2012, 3, 870-879.